Table 1. Overall disease characteristics and by IMDC subgroup.
| Characteristics | Overall (N=143) | Favorable risk (N=46) | Intermediate risk (N=97) |
|---|---|---|---|
| Center, n (%) | |||
| FUSCC | 75 (52.4) | 23 (50.0) | 52 (53.6) |
| FMUUH | 38 (26.6) | 12 (26.1) | 26 (26.8) |
| HMUTH | 30 (21.0) | 11 (23.9) | 19 (19.6) |
| Gender, n (%) | |||
| Male | 106 (75.5) | 36 (78.3) | 70 (72.2) |
| Female | 37 (25.9) | 10 (21.7) | 27 (27.8) |
| Age | |||
| N | 142 | 46 | 96 |
| Mean (SD) | 58.19 (11.12) | 59.41 (9.52) | 57.60 (11.81) |
| Median (Q1, Q3) | 59.50 (51.25, 66.00) | 60.00 (54.50, 66.50) | 59.00 (50.75, 66.00) |
| Min, Max | 25.00–81.00 | 30.00–79.00 | 25.00–81.00 |
| Missing, n (%) | 1 (0.7) | 0 (0) | 1 (1.0) |
| Pathological type, n (%) | |||
| ccRCC | 120 (83.9) | 42 (91.3) | 78 (80.4) |
| Non-ccRCC | 15 (10.5) | 1 (2.2) | 14 (14.4) |
| Missing | 8 (5.6) | 3 (6.5) | 5 (5.2) |
| Maximum tumor size (cm) | |||
| N | 99 | 27 | 72 |
| Mean (SD) | 6.97 (2.57) | 6.84 (2.11) | 7.01 (2.74) |
| Median (Q1, Q3) | 7.00 (4.95, 9.00) | 7.00 (5.10, 7.90) | 7.00 (4.80, 9.00) |
| Range | 1.00–13.00 | 3.00–12.00 | 1.00–13.00 |
| <7, n (%) | 47 (32.9) | 13 (28.3) | 34 (35.0) |
| ≥7, n (%) | 52 (36.4) | 14 (30.4) | 38 (39.2) |
| Missing, n (%) | 44 (30.8) | 19 (41.3) | 25 (25.8) |
| Laterality, n (%) | |||
| Bilateral | 1 (0.7) | 0 (0) | 1 (1.0) |
| Right | 71 (49.7) | 19 (41.3) | 52 (53.6) |
| Left | 68 (47.6) | 26 (56.5) | 42 (43.3) |
| Missing | 3 (2.1) | 1 (2.2) | 2 (2.1) |
| IMDC risk factors, n (%) | |||
| 0 | 46 (32.2) | 46 (100.0) | 0 (0) |
| 1 | 60 (37.7) | 0 (0) | 60 (61.9) |
| 2 | 37 (23.3) | 0 (0) | 37 (38.1) |
| Location of metastatic sites, n (%) | |||
| NA | 10 (7.0) | 2 (4.3) | 8 (8.2) |
| Single metastasis, n (%) | |||
| Lung | 44 (30.8) | 20 (43.5) | 24 (24.7) |
| Bone | 9 (6.3) | 2 (4.3) | 7 (7.2) |
| Others | 19 (13.2) | 5 (10.9) | 14 (14.4) |
| Multiple metastases, n (%) | |||
| Including lung | 44 (30.8) | 14 (30.4) | 30 (30.9) |
| Excluding lung | 17 (11.9) | 3 (6.5) | 14 (14.4) |
| Baseline number of R/M organs, n (%) | |||
| 0 | 10 (7.0) | 2 (4.3) | 8 (8.2) |
| 1 | 72 (50.3) | 27 (58.7) | 45 (46.4) |
| 2 | 39 (27.3) | 15 (32.6) | 24 (24.7) |
| ≥3 | 22 (15.4) | 2 (4.3) | 20 (20.6) |
| Partial treatment, n (%) | |||
| No partial treatment | 100 (69.9) | 31 (67.4) | 69 (71.1) |
| Primary site resection | 14 (9.8) | 3 (6.5) | 11 (11.3) |
| Metastasis site resection | 22 (15.4) | 9 (19.6) | 13 (13.4) |
| Missing | 7 (4.9) | 3 (6.5) | 4 (4.1) |
IMDC, International Metastatic renal cell carcinoma Database Consortium; FUSCC, Fudan University Shanghai Cancer Center; FMUUH, Fujian Medical University Union Hospital; HMUTH, Harbin Medical University Tumor Hospital; SD, standard deviation; ccRCC, clear cell renal cell carcinoma; R/M, relapse/metastasis; NA, not available.